Phase II Study of the Combination of Paclitaxel Poliglumex (CT-2103, Xyotax) and Pemetrexed (Alimta) for the Treatment of Patients With Advanced Non-Small Cell Lung Cancer.

Trial Profile

Phase II Study of the Combination of Paclitaxel Poliglumex (CT-2103, Xyotax) and Pemetrexed (Alimta) for the Treatment of Patients With Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2014

At a glance

  • Drugs Paclitaxel poliglumex (Primary) ; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jan 2014 According to ClinicalTrials.gov record, secondary endpoints were changed to 'time to progression' from 'safety measures'.
    • 11 Jan 2012 Actual patient numbers amended from 12 to 14 as reported by ClinicalTrials.gov.
    • 03 Aug 2009 Results have been presented at the International Association for the Study of Lung Cancer 13th World Conference on Lung Cancer according to a Cell Therapeutics media release. Results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top